Abstract: Monoclonal antibodies or fragments thereof are disclosed, which are binding to the protein P of the human Respiratory Syncytial Virus (RSV) which has a variable region of the heavy chain which has a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No: 1 or SEQ ID 5 or a variable region of the light chain which has a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No:2 or SEQ ID No: 6. Also provided are diagnostic methods ex vivo or in vitro for detection of the viral antigen P of RSV, in which are used the monoclonal antibodies produced and secreted by the hybridomas 2E6/D2 and 6H5/H1. The invention can be used in detection for RSV kits, having the antibodies produced by the mentioned hybridomas.

Abstract: Particulate biomaterial containing particles having geodesic shapes for filling or replacement of bone tissue, and a method of making the particulate biomaterial containing particles having geodesic shapes for filling or replacement of bone tissue, made by rapid prototyping technique (RP), wherein said particles have non-prismatic, semi-spherical geodesic forms.

Abstract: Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as “c-Abl”). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and/or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c-Abl inhibitory compound embodiments.

Abstract: The invention aims at a non-invasive method of early diagnosis of gastric cancer, using as a biomarker the levels of methylation of the DNA sequence of the promoter of the Reprimo-like gene in plasma. The inventors have established the utility of Reprimo-like as a biomarker, and especially as a biomarker for the early detection of gastric cancer, since they have determined that Reprimo-like is consistently silenced in gastric cancer, both in incipient and advanced stages. This silencing is given by methylation of its promoter region, which is detectable in plasma samples, allowing us to measure it as a liquid biopsy in a non-invasive, fast and inexpensive way.

Abstract: Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as “c-Abl”). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and/or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c-Abl inhibitory compound embodiments.

Abstract: The present invention is a aroma recovery equipment from gases exhausted of fermentation vats comprising a first recovery group (100) comprising a first condenser (110) operating at a first temperature of recovered aromas; one second recovery group (200) comprising a second condenser (210) operating at a second temperature of recovered aromas; a cooling group (300) to provide cold by a cooling fluid (301) to said first recovery group (100) via a first fluid connection (302) and to said second recovery group (200) via a second fluid connection (303); control means (400) configured to coordinately control the temperature of said first recovery group (100) and the temperature of said second recovery group (200); and a mobile housing (500) containing said first recovery group (100), said second recovery group (200), said cooling group (300) and said control means (400).

Abstract: The invention consists of a device to evaluate hemodynamic response generated by the spinal cord in response to a suprasensorial stimulus applied to a peripheral nerve (medium or posterior tibial) by the use of functional near-infrared spectroscopy (fNIRS). The device consists of 3 main components, an electrical stimulator, an optical recording unit and a signal processing and control module. The device allows non-invasive, comfortable, harmless, portable, home-based, and low-cost evaluation of changes in local hemodynamic parameters in response to neuronal activation of the spinal cord by electrical stimulation of a peripheral nerve. The invention also includes a corresponding method of using the device and monitoring the spinal function.

Abstract: An autonomous robotic system, and method for automatically monitoring the state of shelves in stores, like retail stores or supermarkets are based on a mobile The mobile robot is capable of autonomously navigating the aisles of a store, with the ability to monitor the condition of product shelves. Specifically, the robotic system solves problems associated with the operation of the shelves, mainly with respect to the detection of incorrect or missing price signs, verification of offer signs, detection of product stock, estimation of product layout, and identification of products misplaced or with errors in the spatial extent assigned to the supplier on a shelf.

Abstract: The present invention is a composition that can form an edible film or an edible liquid coating that can be applied to the surface of fresh fish (fillets or cuts) or fresh seafood. The present invention acts as a physical barrier preventing oxygen, water and microorganisms from entering the food product, and also acts as a bacteriostatic and antioxidant agent.

Abstract: The invention is directed to a method for the early detection of gastric cancer, by detecting the increase in DNA methylation of the promoter region of the microRNA-335-5p in samples obtained non-invasively, preferably in plasma. Thus, it is a contribution for the early detection of gastric cancer, without invasive procedures, with rapid collection of the sample and of the delivery of the results, and of lower cost than the technologies that employ invasive diagnostic techniques to the human and animal body in general.

Abstract: The present invention relates to compounds derived from adamantyl oxadiazoles and the pharmaceutically acceptable solvates, hydrates and salts of same. These compounds are suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11?-HSD1), as well as in the production of a drug for treating conditions and diseases such as high blood pressure, obesity, dyslipidaemia, type 2 diabetes, insulin resistance, glaucoma, metabolic syndrome, cognitive disorders, osteoporosis, immune disorders, depression and other conditions. Also provided is a pharmaceutical composition comprising the compounds and a method for preparing said composition.

Abstract: The present invention consist of an aroma recovery system in an installation with a plurality of fermentation vats for preparing beverages such as white wine, red wine, beers and juices to apply a method of recovering aroma from said fermentation vats; said system comprises at least one connection system, and at least one aroma recovery equipment, wherein said connection system comprises control means such a logic controller (PLC). It is also provided a multiple connection system for connecting said plurality of fermentation vats and said aroma recovery equipment by automatic valves and a method of recovering aroma from fermentation vats of a beverage such as, for example, white wine, red wine, beer and juices.

Abstract: A medical simulator of procedures associated with punctures, for simulation and practical training in puncture interventions, the medical simulator comprising a phantom, an intervention device and a processing system in data communication with the phantom and the intervention device, wherein the phantom comprises at least one target structure arranged for the training of the intervention and means for detecting the intervention device, said detection means being in communication of data with the processing system. The intervention device comprises a real puncture instrument that includes sensing means and detection means in data communication with the processing system. The phantom comprises a structure with at least two components, a simulation assembly that simulates the behavior of tissues and anatomical structures, and a base structure that forms the phantom support, wherein the base structure comprises accommodation and fixation means to house and fix the simulation assembly.

Abstract: The present invention is related to detecting respiratory diseases using molecular markers as prognostic tool of the evolution of respiratory infection cases. Concretely, during the differential diagnostic of respiratory infections caused by the Syncytial Respiratory Virus and human Metapneumovirus, it will be established the expression pattern of the severity markers of IL-3, IL-33 and IL12p40. The expression pattern of the molecular markers can be defined in biological samplers using ELISA assays, flow cytometry or PCR in real time. The confirmation of the etiological agent of the infection in combination to the pattern definition of the molecular markers IL-3, IL-33 and IL12p40 will indicate a prognostic of the disease severity.

Abstract: The present invention relates to a pharmaceutical composition for ameliorating the symptoms and disease of the respiratory infection caused by human Metapneumovirus (hMPV), which comprises at least one agent that neutralizes the function of TSLP and/or TSLPR and/or OX40L and/or CD177 molecules, and a pharmaceutically acceptable excipient, wherein the agent is selected from monoclonal antibodies, biological or synthetic molecules. More specifically, the neutralizing agents are humanized anti-TSLP, anti-TSLPR, anti-OX40L and anti-CD177 monoclonal antibodies. The use of said composition for preparing a medicament for treating or ameliorating the symptoms and disease of patients infected with human Metapneumovirus (hMPV) is also described.

Abstract: The invention relates to a mounting device for adapting a Foley urinary catheter as a percutaneous endoscopic gastrotomy (PEG) catheter for enteral feeding, which comprises a clamp-type radial retention means that holds the catheter to prevent it from migrating into the patient's stomach cavity, said clamp being secured in its position by a locking button for coupling laterally to the catheter and by a perimeter closure ring that is pressed onto the outside of the locking button.

Abstract: A self-centring and energy dissipating seismic isolation device of the elastomeric frictional-type for structures and industrial equipment comprises: first and second metal plates respectively joined, one to the structure or equipment and the other to its foundations, the first metal plate being fixed thereto and the second metal plate being rotatably joined thereto by a column; at least one elastomeric ring between the plates; and a central restrictive bar orthogonally joined to the first plate and extending through the elastomeric ring and through a central through-hole in the second plate, a nut being screwed to the free end of the bar and having a spherical curved-convex bottom in sliding contact and corresponding with a spherical curved-concave inner surface part of the central through-hole. An isolation system can comprise several of these devices and columns or just one pair of devices at the ends of a central column in combination with sliding support pillars.

Abstract: Techniques for quantifying respiration using a wearable device are described. According to some aspects, a wearable device includes multiple thermal sensors thermally coupled to one or more heat spreaders. The wearable device may in some cases be small enough to be wearable between the mouth and nose of the patient, such as via an adhesive attachment to the upper lip. When the patient exhales, air is produced through the mouth and/or through the nose. Each heat spreader may absorb heat of exhaled air which may thermally propagate to a thermal sensor coupled to the heat spreader. By measuring the change in temperature over time measured by the thermal sensors, measures of respiration such as respiratory rate, minute volume and/or tidal volume of the patient may be determined. Such measures may be determined by the wearable device or by an external device to which data is transmitted.

Abstract: Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as “c-Abl”). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and/or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c-Abl inhibitory compound embodiments.

Abstract: A disclosed structural and light concrete includes a binding matrix and light aggregates. The binding matrix has a volume fraction from approximately 20% to approximately 50% of a concrete total volume and include: (1) a Portland Type I, II, III, IV or V cement or a mixture thereof, in a dose of at least 100 kg/m3 of concrete; (2) supplementary cementitious materials in a proportion of up to 4 times by volume of Portland cement; (3) a water component having a volume fraction relative to cement and supplementary cementitious materials in a range from approximately 0.2 to approximately 0.7; and (4) a maximum volume fraction of calcium hydroxide (CH) of approximately 10%. The light aggregates correspond to a volume fraction a range from approximately 30% to approximately 80% of the total concrete volume. Properties include increased compression resistance, decreased density, lower thermal conductivity and higher quotient of density resistance.